Introduction
============

Relaxin which consist of relaxin-1, -2 and -3 and insulin-like peptides (INSL3, 4, 5 and 6) [@B1] is a polypeptide hormone that possesses structural similarity to insulin and is primarily synthesized by the corpus luteum and placenta [@B2]. Relaxin binds to and activates G-protein-coupled receptors (GPCRs): RXFP1(LGR7) and RXFP2(LGR8) [@B3]. Human relaxins H1 and H2 activate both RXFP1 and RXFP2 [@B4], while rat relaxin1 binds weakly to RXFP2 [@B5]. Relaxin H3 binds selectively to RXFP1 as well as RXFP3 (GPCR135) and RXFP4 (GPCR142) [@B6]. RXFP1 and RXFP2 are the two main relaxin receptor isoforms [@B7].

Relaxin activity has been reported in both pregnant and non-pregnant female primates and non-primate vertebrates [@B8], [@B9]. In primates, ovarian relaxin is not required for successful term pregnancy [@B8] however is required to maintain pregnancy in rats and pigs [@B10]. During pregnancy in mice, relaxin is involved in transformation of pubic joint cartilage into a more flexible and elastic interpubic ligament in order to accommodate the enlarging uterus [@B11]. In non-pregnant rats, relaxin administration alone or in combination with estrogen reduces pubic symphysis collagen content, with progesterone antagonizing this effect [@B12]. Meanwhile, during pregnancy in rats, relaxin was reported to regulate collagen catabolism in the pubic symphysis [@B13]. In lower species such as rodents, relaxin action may be more reflective than in humans where serum relaxin level was found to have no link to the generalized joint laxity [@B14].

Relaxin affects tissues\' extracellular matrix components including collagen, H~2~O and hyaluronan. Relaxin increases cervical hyaluronan content by up-regulating the expression of hyaluronic acid synthase [@B15]. This effect will result in loosening of tissues\' dense collagen fiber network. Relaxin has been shown to possess anti-fibrotic action by down-regulating fibroblast activity, increasing collagenases synthesis and inhibit transforming growth factor (TGF-β)-stimulated collagen-l lattice contraction in rat kidney [@B16]. Relaxin up-regulates matrix metalloproteinases (MMP), a family of extracellular proteases that interfere with matrix remodeling by their ability to degrade extracellular matrix components including collagen [@B17]. Relaxin has been reported to stimulate the expression of collagenase-1, MMP-1, MMP-3 [@B18], MMP-9, and MMP-13 in fibrocartilaginous cells [@B19] and MMP-2 in periodontal ligament cells [@B20], [@B21].

Sex-steroids have been reported to affect relaxin receptor expression. In the human endometrium, relaxin receptor isoforms expression vary across the menstrual cycle with low level expressed during the proliferative phase and rises sharply at the time of ovulation [@B22]. In neonatal porcine uterus, estrogen increases RXFP1 mRNA expression, while in cervix, estrogen increases and relaxin decreases the expression of this receptor [@B23]. During late pregnancy in mice, relaxin has no influence on RXFP1 expression [@B24]. Progesterone has been reported to increase the expression of RXFP1 in the pregnant rat uteri [@B25] while estrogen was found to regulate RXFP1 mRNA expression in human cervix at term [@B26].

Knee is another potential target for relaxin action. Currently, little is known with regards to the expression of RXFP1 and RXFP2 in the knee. Wang et al. [@B27] reported that relaxin receptors were expressed in mouse knee fibrocartilage. In humans, relaxin receptors have been identified in the anterior cruciate ligament (ACL) in male and female knee [@B28], with higher expression in female [@B29]. This gender specific difference suggests the influence by female sex hormones. Apart from ACL, the expression of relaxin receptors in other knee structures including patellar tendon and lateral collateral ligament is currently unknown. Together with ACL, they participate in the control of knee stability during movement.

We hypothesized that female sex hormones affect RXFP1 and RXFP2 expression in the patellar tendon and lateral collateral ligament, thus affecting knee laxity. This could explain differences in the incidence of non- contact knee injury between male and female [@B30], and in female at different phases of the menstrual cycle [@B31]. In view of this, we investigated these isoforms expression in the patellar tendon and lateral collateral ligament in rat model in order to provide the mechanism underlying changes in knee laxity under different sex-steroid influence.

Materials and Methods
=====================

Animal Preparation and Hormone Treatment
----------------------------------------

All procedures involving experimental animals were approved by the Faculty of Medicine Animal Care and Use Committee (ACUC), University of Malaya (UM) with ethics number: FIS/22/11/2011/FD(R). Adult female WKY rats weighing 180-220 grams, obtained from the Animal House, Faculty of Medicine, UM were caged in a group of six, in a clean and well ventilated standard environment of 12 hours light: dark cycle. The animals had free access to soy-free diet (Gold Coin Pellet) and tap water *ad libitum*. Female WKY rats were ovariectomized ten days prior to steroid treatment to eliminate the effect of endogenous sex-steroids as previously described [@B32].

The animals were then divided into 8 groups (n=6 per group): Groups 1-4 received different doses of estrogen (0.2, 2, 20 and 50 µg/kg) for three days with administration of 0.2 μg/kg estrogen was intended to achieve physiological plasma estrogen level in female rats [@B32]., Similarly, administration of higher estrogen doses were intended to produce hyperestrogenic conditions [@B33]. Group 5 received 3 days treatment with 4 mg/kg progesterone, which was administered to achieve the maximum physiological plasma level in female rats during oestrous cycle [@B32], [@B34]. Groups 6-7 received 3 days treatment with 125 and 250 μg/kg testosterone, [@B35], which will achieve a plasma level lower than the physiological level reported in the male rats (following 500 μg/ml testosterone administration) [@B36]. In humans, the premenoupasal plasma testosterone level was reported to be between 0.6 to 0.7 ng/ml [@B37]. In view of this, the doses used in this study i.e.125 μg/kg and 250 μg/kg testosterone would contribute to physiological and supra-physiological plasma levels in female rats respectively (Refer Table [1](#T1){ref-type="table"} for plasma level for the related doses of hormones administered). Group 8 is a control group which received peanut oil (vehicle) for three days. All drugs were dissolved in peanut oil and were administered via subcutaneous injection behind the neck. To substantiate the amount of hormone reaches the blood circulation following subcutaneous injection,blood samples were withdrawn by heart puncture immediately following decapacitation and plasma concentrations of each hormone were determined by radioimmunoassay (RIA) in both treated and non-treated groups (control).

mRNA Expression Analysis by Real Time PCR (qPCR)
------------------------------------------------

Patellar tendon, also known as patellar ligament which connects patellar to tibia tuberosity and lateral collateral ligament (LCL), which connects lateral epicondyle of the femur to the head of the fibula at the lateral side of the knee joint were harvested from rat\'s left hind leg. Both ligaments are extracapsular. Tissues were subsequently separated from their bony attachment and were immediately rinsed with 0.1% phosphate buffer. These tissues were kept in the RNALater solution (Ambion, USA) prior to RNA extraction. Total RNA was isolated from 30 mg (wet weight) using Ribo pure kit (Ambion, USA). The RNA purity and concentration was assessed by 260/280 UV absorption ratios (Gene Quant 1300, UK). One step real time PCR was used to evaluate gene expression, with the application of TaqMan® RNA-to-CT 1-Step Kit. Hprt1 and GAPDH were used as reference genes. TaqMan primer and probe for RXFP1, RXFP2, GAPDH and Hprt1 were obtained from predesigned assays from Applied Biosystems, USA. All experiments were done in 3 biological replicates. PCR program include 15 minutes at 48ºC reverse transcriptase, 10 minutes at 95ºC activation of ampli Taq gold DNA polymerase, denaturation at 95ºC for 15 second and annealing at 60ºC for 1 minute. Denature and annealing steps were performed for 40 cycles. Step one plus real time PCR machine, master mix and assays were purchased from Applied Biosystems, USA. The fold change of each target per average of GAPDH and Hprt1 was calculated and was considered as the mRNA expression level of the target gene. Data was analyzed according to Comparative Ct (2^-ΔΔCt^) method [@B38], where amplification of the target and of the reference genes were measured in the samples and reference. Measurements were normalized using GenEx software. Data Assist v3 software from Applied Biosystems, USA was used to calculate the RNA fold changes.

Protein Expression Analysis by Western Blotting
-----------------------------------------------

Patellar tendon and lateral collateral ligament were removed from their bony attachment of rat\'s left hind leg as earlier described. These tissues were then snapped frozen in liquid nitrogen and stored at -80°C prior to protein extraction. The total amount of protein was extracted from 50 mg tissue (wet weight). Following total protein extraction with PRO-PREP (Intron, UK), equal amount of protein from each tissue lysate were mixed with a loading dye, boiled for 5 minutes and separated by SDS-PAGE 12%. The protein was then transferred onto a PVDF membrane (BIORAD, UK) and blocked with 5% BSA for 90 minutes at room temperature. The membrane was exposed to rabbit polyclonal primary RXFP-1/LGR7 antibody (Abcam, UK), mouse polyclonal RXFP2/LGR8 (Abcam, UK) and rabbit anti-mouse beta actin (Abcam, UK) diluted at 1:1000 in PBS containing 1% BSA and tween-20 for 90 minutes. Blots were washed three times with each lasted for five minutes, and were then incubated with anti-rabbit and anti-mouse horseradish peroxidase conjugated secondary antibodies (Santa Cruz) at a dilution of 1:2000, for 1 hour. The membrane was then washed and subjected to Opti-4CN™ Substrate Kit from Bio-Rad to visualize the protein bands. Photos of the blots were captured by a gel documentation system and the density of each band was determined using Image J software. Ratio of each target band/β actin was calculated and was considered as the expression level of the target proteins.

Statistical Analysis
--------------------

One way Anova, with Tukey\'s post hoc test, was used to determine the level of significance with p\< 0.05 was considered as significant. Meanwhile, Shapiro-Wilk test was further applied to evaluate data normality and homogeneity [@B39]. In this test, p value greater than α level of 0.05 indicates that data came from a normally distributed population. For real time PCR and Western blotting, 6 rats were used per treatment groups. Density of each band in Western blotting was analyzed using Image J software, and the results were presented as the ratio of the target proteins to β-actin.

Results
=======

Plasma Sex-Steroid Levels following Subcutaneous Hormone Injection
------------------------------------------------------------------

In table [1](#T1){ref-type="table"}, the average hormones level in the blood in different groups of treatment is shown. Our findings indicate that serum levels of estrogen and testosterone correlate with the doses administered. Subcutaneous injection of 0.2μg/kg estrogen resulted in plasma level of approximately two times higher than the control while injection of 4 mg progesterone resulted in five times higher level than the control.

RXFP1 and RXFP2 Proteins Expression in the Patellar Tendon and Lateral Collateral Ligament
------------------------------------------------------------------------------------------

In figure [1](#F1){ref-type="fig"}, the expression of RXFP1 protein is the highest in the lateral collateral ligament of progesterone treated rats with 1.75 fold increase as compared to control. Treatment with estrogen at 0.2 μg/kg resulted in a slight but significant increase in the expression of RXFP1 protein as compared to control (p\<0.05). Treatment with higher estrogen doses (\>2μg/kg) resulted in a dose-dependent increase in RXFP1 protein expression with 43 and 100 percent increase following treatment with 20 and 50μg/kg estrogen respectively. Testosterone treatment resulted in a significant decrease in the expression of RXFP1 (0.54 and 0.45 fold increase following subcutaneous administration of 125 and 250μg/kg testosterone respectively).

In figure [3](#F3){ref-type="fig"}, the expression of RXFP1 protein in the patellar tendon following treatment with 4mg progesterone is 2.71 folds higher than the control. Estrogen treatment resulted in a dose-dependent increase in this protein expression (1.25 to 2.67 fold increase following treatment with estrogen at doses between 0.2 to 50μg/kg). Testosterone treatment resulted in a dose-dependent decrease in RXFP1 protein expression (0.65 and 0.51 fold decrease) following treatment with 125 and 250μg testosterone respectively. The expression of RXFP1 protein in the patellar tendon was higher than the lateral collateral ligament.

In figure [5](#F5){ref-type="fig"}, the expression of RXFP2 protein in the lateral collateral ligament was the highest following treatment with progesterone (0.93 fold increase as compared to control) (p\<0.05). A dose-dependent increase in the expression of RXFP2 protein was observed following treatment with increasing doses of estrogen (0.93 to 1.09 fold increase with estrogen doses between 0.2 to 50μg/kg). Treatment with 0.2μg/kg estrogen did not result in a significant increase in RXFP2 protein expression as compared to control. Treatment with 125 and 250μg/kg testosterone resulted in a significant decrease in the expression of RXFP2 protein, with 13 and 14 percent reduction as compared to control.

In figure [7](#F7){ref-type="fig"}, the expression of RXFP2 protein in the patellar tendon was the highest following progesterone treatment (1.28 fold increase as compared to control). Treatment with increasing doses of estrogen resulted in a dose-dependent increase in RXFP2 protein expression; although the increase observed following 0.2μg/kg estrogen treatment was not significantly differ from the control. A significant reduction in RXFP2 protein expression was noted following treatment with 250μg testosterone, which was 21.9 percent lower than the control. In the patellar tendon, the expression of RXFP1 exceeds RXFP2 by more than two times in particular following treatment with high estrogen doses (20 and 50μg/kg) and progesterone.

RXFP1and RXFP2 mRNAs Expression in the Patellar Tendon and Lateral Collateral Ligament
--------------------------------------------------------------------------------------

In figure [2](#F2){ref-type="fig"}, following progesterone treatment, the expression of RXFP1 mRNA in the lateral collateral ligament was 2.71 folds higher as compared to control. The lowest expression was noted following treatment with 250μg testosterone, which was 27 percent lesser than the control. Treatment with estrogen resulted in a dose-dependent increase in RXFP1 mRNA expression (1.21 to 2.13 fold increase following treatment with 0.2 to 50μg/kg estrogen).

In figure [4](#F4){ref-type="fig"}, the expression of RXFP1 mRNA in the patellar tendon was the highest following treatment with progesterone (2.86 fold increase as compared to control). Treatment with testosterone at 125 and 250μg/kg resulted in a significant reduction in RXFP1 mRNA expression as compared to control (p\<0.05), with 16 and 26 percent decrease respectively. Estrogen administration resulted in a dose-dependent increase in the expression of RXFP1 mRNA (1.63 to 2.23 fold increase following treatment with 0.2 to 50μg/kg estrogen), which were significantly higher than the control (p\<0.05). The level of expression of RXFP1 in the patellar tendon was higher than its expression in the lateral collateral ligament.

In figure [6](#F6){ref-type="fig"}, the expression of RXFP2 mRNA in the lateral collateral ligament was increased following progesterone treatment which was 1.58 fold higher than the control. Estrogen treatment resulted in a dose-dependent increase in RXFP2 mRNA expression (1.13 to1.43 fold increase following treatment with 0.2 to 50μg/kg estrogen). Treatment with low dose estrogen (0.2μg/kg) however did not result in any significant change in the mRNA expression, while treatment with higher estrogen doses (\>2μg/kg) resulted in a significant increase in the mRNA level as compared to control. Testosterone treatment at 125 and 250μg/kg resulted in a significant decrease in RXFP2 mRNA expression as compared to 0.2 μg/kg estrogen and the control (p\<0.05).

In figure [8](#F8){ref-type="fig"}, the expression of RXFP2 mRNA in the patellar tendon was the highest following treatment with progesterone (2.28 fold increase as compared to control). Estrogen treatment resulted in a dose-dependent increase in RXFP2 expression (1.13 to 2.01 fold increase following treatment with 0.2 to 50μg/kg estrogen). Treatment with 125 and 250μg/kg testosterone resulted in a significant reduction in RXFP2 mRNA expression (0.79 and 0.5 fold- respectively) as compared to control. RXFP2 mRNA expression in the patellar tendon exceeds its expression in the lateral collateral ligament only following treatment with 50μg/kg estrogen and progesterone.

Discussion
==========

Our findings have revealed the followings: (i) The expression of RXFP1 protein and mRNA in knee lateral collateral ligament and patellar tendon were up-regulated by estrogen and progesterone, and were down-regulated by testosterone (ii) RXFP2 protein and mRNA expression were up-regulated by estrogen at doses exceeding 2μg/kg and progesterone. Treatment with 0.2μg/kg estrogen however had no significant effect on the expression of this receptor isoform, (iii) The expression of RXFP1 protein and mRNA in the patellar tendon under the influence of estrogen and progesterone was higher than its expression in the lateral collateral ligament, (iv) No significant changes in RXFP2 expression was noted between patellar tendon and lateral collateral ligament except following treatment with 50μg/kg estrogen and progesterone, where higher expression was noted in the former than the latter and (iv) RXFP1 is the main isoform expressed in the patellar tendon and lateral collateral ligament of the rat knee joint.

The effect of relaxin on ligament laxity has long been reported [@B40]. The first evidence was documented by Hisaw in 1926 where relaxin infusion in mice was found to cause relaxation of the pelvic ligament [@B41]. Research related to relaxin effect on knee joint laxity has become increasingly important in the recent years due to the reported increase in the incidence of non-contact knee injury among the female athletes. Recent evidence suggested that plasma relaxin level correlates with the increase in incidence of ACL tear in elite female athletes [@B42]. In addition to knee, the laxity of trapezial-metacarpal joint in humans [@B14] and pubic ligaments in mice [@B11] has also been reported to change with changes in plasma relaxin level.

The influence of female sex-hormones on relaxin action in the knee ligaments has been proposed. *In-vitro* binding assay has revealed that relaxin binding to the female ACL was higher than male ACL. This finding was supported by the increase in the number of relaxin receptors expressed in the female ACL as compared to male [@B29]. Quantitation of relaxin receptors by radioligand binding assay in the human ACL fibroblast cells has revealed that relaxin binding was present in four out of five female ACL fibroblast as compared to one out of five male ACL fibroblast [@B28]. The direct influence of estrogen on ACL laxity has been documented by Dragoo et al [@B43] where three weeks combined infusion of estrogen and relaxin to the guinea pigs has resulted in increased anterior tibial dislocation, indicating an increase in ACL laxity. Meanwhile, in rabbit temporomandibular joint and pubic symphysis, concomitant administration of relaxin with estrogen was found to cause loss of glycosaminoglycans and collagen from these tissues, which will lead to an increase in the ligament laxity. Progesterone administration meanwhile prevented this effect [@B18].

Although this study has not provided direct evidence of an increase in the expression of relaxin receptors in the ACL under sex-steroid effect, we have for the first time shown that estrogen and progesterone upregulate the expression of relaxin receptor isoforms (RXFP1 and RXFP2) in the patellar tendon and lateral collateral ligament. In other tissues including uterus [@B25] and cervix [@B26], estrogen was also reported to upregulate the expression of the relaxin receptors. In this study, modulation of RXFP1 and RXFP2 expression by sex-steroids could provide the basis underlying the effect of these hormones on knee joint laxity. Recently, relaxin was also found to have significant effect on the patellar tendon stiffness in healthy, young and normally menstruating women [@B44]. Although the actual mechanism is unknown, this effect could possibly be mediated through upregulation of RXFP1 and RXFP2 by sex-steroids, which levels fluctuate throughout the menstrual cycle. The mechanisms that lead to the changes in knee ligament laxity following the binding of relaxin to its receptors have been earlier discussed (*introduction section*).

Our findings have important implication as it could help to explain differences in the incidence of non-contact knee injury between male and female. Female was reported to have two to ten times higher risk of injury than male and is related to phases of the menstrual cycle [@B31] which pointed towards the involvement of sex-steroids. The effect of estrogen on RXFP1 and RXFP2 expression in the patellar tendon and lateral collateral ligament of rats\' knee confirmed the involvement of this hormone in modulating knee laxity. At low dose (0.2μg/kg), which correlate with the plasma estrogen level of 69.7 ± 0.12pg/ml (table [1](#T1){ref-type="table"}), the expression of RXFP1 was higher than the control although no significant changes in RXFP2 expression were noted. The mean reported plasma estrogen level in the early follicular phase of the menstrual cycle was 31 pg/ml (0.31 X 10^-4^μg/ml) [@B45]. In rat at proestrous, estrogen level was found to be higher at 40.5 pg/ml (0.45 X 10^-4^μg/ml) [@B46]. In view that 0.2μg/kg estrogen administration resulted in the plasma estrogen level of 69.7 pg/ml, which was slightly higher than the level observed in humans and rats at the follicular phase and proestrus stage respectively, there is a possibility that this level could affect knee ligament laxity via upregulating the expression of relaxin receptor isoforms rendering the tissue to be more sensitive towards relaxin action.

Meanwhile, administration of 2, 20 and 50 μg/kg estrogen resulted in the circulating plasma level of 195.2 ± 0.31, 267.7 ± 0.76 and 329.4 ± 2.33 pg/ml respectively (table [1](#T1){ref-type="table"}). Treatment with estrogen at doses exceeding 2μg/kg resulted in higher expression of RXFP1 and RXFP2 as compared to the control and 0.2μg/kg estrogen. High estrogen level in the blood could be achieved at the time of ovulation, with the reported level of 400pg/ml (0.4 X 10^-3^μg/ml) [@B45]. Shultz et al [@B47] reported that high incidence of non-contact knee injury occur in the pre-ovulatory phase, which suggested that increased estrogen level may have significant impact on the knee ligament laxity. Several other findings have also reported that increased incidence of non-contact knee injury during the ovulatory phases of the cycle [@B48]-[@B50] was related to the effect of high estrogen doses on knee ligament laxity. Estrogen- induced upregulation of relaxin receptors will augment relaxin effect on the knee.

High plasma estrogen can be achieved following consumption of oral contraceptive pills (OCP) that contains 15 to 50 μg estrogen [@B51]. In the female athletes, OCP is consumed for birth control purpose and to prevent menstruation in order to improve their physical performance [@B52]. Few studies have reported that OCP intake could influence knee laxity; however their findings seem to be conflicting. Hicks-Little et al, [@B53] and Cammarata et al [@B54] reported that female on OCP tend to have higher knee laxity, while others reported the opposite [@B55]. Meanwhile, few other studies found no relationship between OCP consumption and knee ligament laxity [@B51], [@B56]. Differences in sex-steroid content between different OCP formulations could be the reason for this variability.

While estrogen has been shown to affect ACL laxity in the animal model [@B43], little is known with regards to the effect of progesterone and testosterone on knee ligament laxity. Dragoo et al, [@B57] measured serum relaxin concentration (SRC) in elite collegiate female athletes and had observed a positive correlation between SRC and serum progesterone concentration in athletes who are oligomenorrheic, eumenorrheic, not on oral contraceptive and have ovulatory cycle., In this study, serum progesterone level was measured to confirmed luteal phase measurement of relaxin as relaxin levels are known to be higher in this phase. Other studies involving female athletes have also indicated that knee laxity was increased during ovulation and in the luteal phase of the menstrual cycle [@B53]. Meanwhile, a positive correlation between changes in knee laxity and knee joint load has been reported from follicular phase to ovulation, and from ovulation to the luteal phase [@B49], where the latter phase is associated with high serum progesterone level. Our findings which revealed an up-regulation of RXFP1 and RXFP2 isoforms in the patellar tendon and lateral collateral ligament by progesterone further support these observations. The increase in these isoforms expression in the collateral ligaments predisposes the knee towards non-contact injury especially during excessive varus or valgus movement.

Progesterone upregulation of RXFP1 and RXFP2 expression in the knee was supported by findings in other tissues including the pregnant rat uteri, where this hormone was found to cause an increase in RXFP1 expression in the myometrium [@B25]. In the mammary glands, progesterone was reported to stimulate relaxin receptor expression which resulted in reduced breast laxity. This effect is due to a decrease in the collagen content of the mammary gland\'s extracellular matrix in the presence of relaxin [@B58]. In this study, the plasma level achieved following subcutaneous progesterone injection was 23.67 ± 0.13 ng/ml, which was slightly higher than the maximum plasma level reported during the luteal phase of the cycle in premenopausal female, at 17.02 ng/ml [@B59]. This indicate that the level of progesterone in the luteal phase can cause an increase in knee laxity, rendering the knee to be more susceptible towards a non-contact injury.

Finally, we have also observed that RXFP1 and RXFP2 expression in both patellar tendon and lateral collateral ligament was down-regulated by testosterone and this effect was dose-dependent. In the female, the presence of androgen receptor was reported in the ACL [@B60], suggesting that testosterone could influence knee laxity. Testosterone level was found to fluctuate throughout the menstrual cycle, with the highest level noted in the luteal phase [@B61].Down-regulation of RXFP1 and RXFP2 expression by testosterone in the patellar tendon and lateral collateral ligament indicated that knee laxity could be reduced under the influence of this hormone. A recent finding by O\'Leary et al, [@B62] indicated that prolonged aerobic exercise in women with normal menstrual cycle can induce a short-term elevation in plasma testosterone level. We hypothesized that a continuous short-burst in plasma testosterone may result in down-regulation of relaxin receptors in these knee structures, thus could help to reduce knee laxity in exercising women. In addition to this, testosterone has also been reported to increase the strength of the muscles that control knee joint movement [@B63]. Taken together, these findings may explain increased knee joint stiffness in female following testosterone administration.

In conclusion, our study has provided novel evidences that sex-steroid affect RXFP1 and RXFP2 expression in the patellar tendon and lateral colateral ligament of the rat knee joint.These findings are important as it may help to provide the basis underlying increased in incidence of non-contact knee injury in female as compared to male and in female at different phases of the menstrual cycle. Precaution however should be taken when projecting these findings to humans as recent evidence suggested that there was apparently no relationship between serum relaxin and joint laxity [@B14].

This study is supported by PPP grant, (PV104/2012A), University of Malaya, Kuala Lumpur, Malaysia.
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###### 

Plasma sex steroid level following subcutaneous hormone injection. Values were given as mean ± standard error of mean. E - estrogen, P - progesterone and T - testosterone. The level of hormones in the blood correlates with the amount injected via the subcutaneous route.

  Treated samples    Hormone level (Mean±SD)
  ------------------ -------------------------
  **Estrogen**       
  Control            39.4±0.14 pg/ml
  0.2 µg/kg E        69.7±0.12 pg/ml
  2 µg/kg E          195.2±0.31pg/ml
  20 µg/kg E         267.7±0.76 pg/ml
  50 µg/kg E         329.4±2.33 pg/ml
  **Progesterone**   
  Control            4.18±0.11 ng/ml
  4 mg/kg P          23.67±0.13 ng/ml
  **Testosterone**   
  Control            0.25±0.004 ng/ml
  125 µg/kg T        0.89±0.005 ng/ml
  250 µg/kg T        1.07±0.002 ng/ml
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